RQA membership is a great way to connect with your QA colleagues.
More information
Join the community - networking, discussion and more. Open to all.
More information
Could you write an interesting article for the RQA community?
More information17th November 2026
The European Medicines Agency (EMA) has published updates from three key committees covering human medicines, veterinary products and pharmacovigilance. The Committee for Medicinal Products for Human Use (CHMP) recommended seven new medicines for approval, including treatments for lung cancer and hypertension, alongside 11 extensions of existing therapeutic indications. The Committee for Veterinary Medicinal Products (CVMP) issued five positive opinions for new veterinary medicines, including treatments and vaccines for horses, dogs and pigs, and progressed work on antimicrobial resistance and regulatory guidance. Meanwhile, the Pharmacovigilance Risk Assessment Committee (PRAC) initiated safety reviews of Deanxit, used to treat depression and anxiety, and human normal immunoglobulin medicines following reports of serious adverse reactions. Together, the updates reflect ongoing regulatory activity to support medicine availability, strengthen safety monitoring and maintain standards across human and veterinary healthcare.
Links: